Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

  Email address:
   

Free Report

White Paper_2017_State of China Life Science

State of China Life Science - 2017H1

Over $10B invested in last 18 months! Download free report on life science investment in China.

Week in Review: Tasly Buys Stake in TCM Maker for $25 Million

publication date: Oct 5, 2013
 | 
author/source: Richard Daverman, PhD

Deals and Transactions

Tianjin Tasly Pharma (SHA: 600535) acquired a 45% stake in Henan New Century Pharmaceutical for 151 million RMB ($24.7 million) (see story). New Century is a TCM maker whose primary product is Xingnaojing injection, a treatment for stroke. The drug has a wide range of indications combined with minimal side effects. Xingnaojing injection is the second best-selling cerebral TCM product in China. Tasly’s portfolio already includes salvianolic acid injection, also a stroke treatment.

Hefei Life Science will fund the China clinical development of a drug eluting stent produced by Micell Technologies, a North Carolina interventional cardiology device maker (see story). Once the stent is approved by the CFDA, Micell will continue to manufacture the MiStent SES. Sinopharm will be responsible for distribution, and SinoMedCare of Shanghai will contribute marketing and sales support. The agreement includes annual purchase commitments after the product is approved for sale. Hefei Life Science was established to bring high-tech bio-pharmaceutical projects with good market prospects to Hefei Life Science Park.

Company News

Sanofi (NYSE: SNY) is taking the “big picture” approach to emerging markets, according to its CEO, refusing to stop investing in developing countries because of pricing pressure and government crackdowns (see story). In fact, Sanofi will continue to seek acquisitions in emerging markets, said Chris Viehbacher, Sanofi’s CEO, and it will presumably also forge partnerships, as it has done in China. There will be occasional setbacks, he continued, but the markets are too important to ignore.

CRO/CMO News

Parexel (NSDQ: PRXL), the US clinical-stage CRO, has formed Dĭng Huī China Trials Solution, a Beijing company that is dedicated entirely to conducting trials that will gain product approvals in China (see story). The rest of Parexel’s China offices participate in global clinical trials as well as China-specific tests.

Trials and Approvals

Lee's Pharma (HK: 0950) of Hong Kong reported that its China registration study of Trazodone as a treatment for depression met its primary endpoint (see story). Lee’s in-licensed Trazodone (Trittico®) from Italian pharma Angelini. The Trazodone cohort of the trial showed a statistically significant improvement over placebo on a depression measurement scale.

Disclosure: none.  


 


Share this with colleagues:

 

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes


Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China